

Mauro Bombaci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127209/publications.pdf>

Version: 2024-02-01

35
papers

1,195
citations

471509

17
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

1852
citing authors

#	ARTICLE	IF	CITATIONS
1	Elucidating the 3D Structure of a Surface Membrane Antigen from <i>Trypanosoma cruzi</i> as a Serodiagnostic Biomarker of Chagas Disease. <i>Vaccines</i> , 2022, 10, 71.	4.4	0
2	The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. <i>Frontiers in Medicine</i> , 2022, 9, 850858.	2.6	3
3	Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. <i>IScience</i> , 2022, 25, 104239.	4.1	7
4	ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease. <i>Human Molecular Genetics</i> , 2021, 30, 1175-1187.	2.9	11
5	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. <i>Journal of Controlled Release</i> , 2021, 330, 587-598.	9.9	33
6	Structure, Immunoreactivity, and In Silico Epitope Determination of SmSPI S. mansoni Serpin for Immunodiagnostic Application. <i>Vaccines</i> , 2021, 9, 322.	4.4	4
7	Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	108
8	A new generation of brain-targeted nanoparticles for cholesterol delivery in huntington's disease: kinetics, drug release and behavioral effects in mouse models. , 2021, , .		0
9	ADAM10 activity at the huntington's disease presynapse. , 2021, , .		1
10	Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response. <i>Frontiers in Immunology</i> , 2021, 12, 785941.	4.8	38
11	A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer. <i>IScience</i> , 2020, 23, 101250.	4.1	14
12	Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6 ⁺ B helper T cells in systemic lupus erythematosus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7305-7316.	7.1	35
13	Abstract 2829: A novel candidate for immunotherapy mediating the balance between the immune system and cancer. , 2020, , .		0
14	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. <i>Liver International</i> , 2019, 39, 2124-2135.	3.9	10
15	Computation and Selection of Optimal Biomarker Combinations by Integrative ROC Analysis Using CombiROC. <i>Methods in Molecular Biology</i> , 2019, 1959, 247-259.	0.9	6
16	Enhancing Antibody Serodiagnosis Using a Controlled Peptide Coimmobilization Strategy. <i>ACS Infectious Diseases</i> , 2018, 4, 998-1006.	3.8	25
17	RACK1 Specifically Regulates Translation through Its Binding to Ribosomes. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	47
18	CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. <i>Scientific Reports</i> , 2017, 7, 45477.	3.3	80

#	ARTICLE	IF	CITATIONS
19	Lack of evidence for post-vaccine onset of autoimmune/lymphoproliferative disorders, during a nine-month follow-up in multiply vaccinated Italian military personnel. <i>Clinical Immunology</i> , 2017, 181, 60-66.	3.2	5
20	TCTN2: a novel tumor marker with oncogenic properties. <i>Oncotarget</i> , 2017, 8, 95256-95269.	1.8	9
21	Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis. <i>PLoS ONE</i> , 2015, 10, e0137927.	2.5	9
22	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1885-1897.	3.8	38
23	Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.015693.	3.8	115
24	Surface Interactome in <i>Streptococcus pyogenes</i> . <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.015206.	3.8	9
25	A multivariate analysis of protein microarrays for signature selection profiles. <i>EMBnet Journal</i> , 2012, 18, 124.	0.6	0
26	Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. <i>FASEB Journal</i> , 2009, 23, 3100-3112.	0.5	47
27	Protein Array Profiling of Tic Patient Sera Reveals a Broad Range and Enhanced Immune Response against Group A Streptococcus Antigens. <i>PLoS ONE</i> , 2009, 4, e6332.	2.5	60
28	<i>Streptococcus pyogenes</i> pili promote pharyngeal cell adhesion and biofilm formation. <i>Molecular Microbiology</i> , 2007, 64, 968-983.	2.5	206
29	Identification of major proteins secreted by <i>Cryptococcus neoformans</i> . <i>FEMS Yeast Research</i> , 2006, 6, 645-651.	2.3	23
30	MyD88 and TLR2, but not TLR4, are required for host defense against <i>Cryptococcus neoformans</i> . <i>European Journal of Immunology</i> , 2005, 35, 870-878.	2.9	139
31	Characterization of Two Novel Cryptococcal Mannoproteins Recognized by Immune Sera. <i>Infection and Immunity</i> , 2005, 73, 7348-7355.	2.2	39
32	Induction of T Helper Type 1 Responses by a Polysaccharide Deacetylase from <i>Cryptococcus neoformans</i> . <i>Infection and Immunity</i> , 2003, 71, 5412-5417.	2.2	22
33	Identification and Cloning of a Cryptococcal Deacetylase That Produces Protective Immune Responses. <i>Infection and Immunity</i> , 2002, 70, 2383-2391.	2.2	47
34	Synthetic Carbohydrate Binding Agents (CBAs) Prevent SARS-CoV-2 Entry by Inhibiting Binding of the Spike Protein to the ACE2 Receptor. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
35	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0